Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page has removed a reference to a study on the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer.
    Difference
    0.6%
    Check dated 2025-06-27T00:48:23.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.
    Difference
    0.9%
    Check dated 2025-06-19T20:09:55.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated to include new information regarding the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer, along with a revision update from v2.16.1 to v2.16.2.
    Difference
    0.7%
    Check dated 2025-06-05T11:27:44.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The page has been updated to include information about the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, and it now features new references related to pembrolizumab and a randomized trial for non-small-cell lung cancer. Additionally, an older reference has been removed.
    Difference
    8%
    Check dated 2025-05-29T06:14:36.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The web page has removed key references to clinical trials involving Pembrolizumab and its comparison with other treatment methods for non-small-cell lung cancer.
    Difference
    1%
    Check dated 2025-05-22T03:57:21.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The page has added information regarding the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer, referencing a specific study published in the New England Journal of Medicine.
    Difference
    0.6%
    Check dated 2025-05-14T23:59:11.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.